8-K: GT Biopharma Amends Private Placement, Expands Funding to $5.95 Million with New Investor

GT Biopharma, Inc. has amended its previously announced private placement, increasing the aggregate purchase price to $5.95 million and adding a new purchaser, while also expanding the potential for future funding through Greenshoe Rights.

Summary

• GT Biopharma, Inc. (the 'Company') amended its Securities Purchase Agreement on May 21, 2025, increasing the private placement offering.
• The aggregate purchase price for the offering was increased from $5,450,000.00 to $5,950,000.00.
• The number of Series L 10% Convertible Preferred Stock shares issuable was increased from 6,056 to 6,612, with an aggregate stated value rising from $6,055,555.56 to $6,611,111.00.
• A new purchaser, Robert A. Marzilli, was added to the agreement, joining the original purchasers.
• The offering includes Series L 10% Convertible Preferred Stock, Common Warrants, and Vesting Warrants.
• Purchasers retain Greenshoe Rights to acquire additional Preferred Stock with an aggregate stated value of up to $24,018,349 for a purchase price of $21,616,514.
• The Company filed a Certificate of Increase on May 22, 2025, raising the designated shares of Series L Preferred Stock from 28,056 to 30,630.
• The securities were offered privately under Rule 506(b) of Regulation D.
• The Company is obligated to file a registration statement for the public resale of common stock issuable upon conversion of Preferred Stock and exercise of Warrants within 30 days of each closing, to become effective within 90 days of filing.

Sentiment

Score: 7

Explanation: The successful increase of a private placement and the addition of a new investor are positive for a biopharma company's liquidity and ability to fund operations. While convertible securities imply future dilution, securing capital is critical for this industry.

Positives

• Successfully increased the size of the private placement, securing additional capital for the Company.
• Addition of a new purchaser, Robert A. Marzilli, indicates continued investor interest and confidence.
• The existence of Greenshoe Rights provides a mechanism for potential future capital infusion up to an additional $21,616,514.
• The capital raise provides necessary funding for a biopharma company, which typically has high R&D costs.

Negatives

• The issuance of convertible preferred stock and warrants will lead to dilution for existing common stockholders upon conversion and exercise.
• The 10% convertible preferred stock carries a significant dividend, which will be a recurring financial obligation.

Risks

• Potential future dilution of common stock shareholders upon conversion of Series L Preferred Stock and exercise of Warrants.
• The Company's ability to effectively utilize the raised capital to advance its pipeline and achieve milestones is crucial for long-term value creation.
• Reliance on private placements for funding may indicate challenges in accessing public markets or a preference for specific investor relationships.

Future Outlook

The Company plans to file a registration statement with the SEC covering the public resale of common stock issuable upon conversion of the Preferred Stock and exercise of the Warrants within 30 days after the initial closing and after each closing of the exercise of a Greenshoe Right. This registration statement is expected to become effective no later than 90 days after filing.

Management Comments

• Michael Breen, Executive Chairman & Chief Executive Officer, signed the Certificate of Increase and the First Amendment to Securities Purchase Agreement.
• Alan Urban, Chief Financial Officer, signed the Form 8-K.

Industry Context

This capital raise is typical for a biopharma company like GT Biopharma, which often requires significant funding for research, development, and clinical trials. The use of convertible preferred stock and warrants is a common financing mechanism in the biotech sector to attract investors, offering potential upside while providing a preferred return. The ability to expand the offering and attract new investors suggests a degree of confidence in the company's prospects within the competitive biopharma landscape.

Comparison to Industry Standards

• The use of convertible preferred stock and warrants is a standard financing instrument in the biotechnology industry, particularly for companies in development stages that require substantial capital without immediate revenue streams.
• The 10% dividend on the Series L Preferred Stock is within the typical range for such instruments, reflecting the risk profile of early to mid-stage biopharma investments.
• The inclusion of Greenshoe Rights is a common feature in private placements, allowing for flexibility to raise additional capital from existing investors if demand or future needs arise, aligning with industry practices for staged financing.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential future dilution due to the conversion of preferred stock and exercise of warrants, but improved company liquidity and funding for operations.
• Investors (Purchasers): Receive preferred stock with a 10% dividend and warrants, offering potential upside and a preferred return on their investment.

Next Steps

• The Company will file a registration statement with the SEC within 30 days after the initial closing and after each closing of the exercise of a Greenshoe Right.
• The registration statement is expected to become effective no later than 90 days after filing.

Key Dates

Recommendation

Keywords

GT Biopharma, Private Placement, Convertible Preferred Stock, Warrants, Capital Raise, SEC Filing, Form 8-K, Regulation D, Greenshoe Rights, Biopharma, Financing, Equity Offering